Effect of composite yogurt enriched with acacia fiber and Bifidobacterium lactis

World Journal of Gastroenterology

Volumn 18, Issue 33, 2012, Pages 4563-4569

  Min, Yang Won ^a   Park, Sang Un ^a   Jang, Yeon Sil ^a   Kim, Young Ho ^a   Rhee, Poong Lyul ^a   Ko, Seo Hyun ^b   Joo, Nami ^b   Kim, Sun Im ^b   Kim, Cheol Hyun ^c   Chang, Dong Kyung ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Sookmyung Women's University   (South Korea)

^c Dankook University   (South Korea)

Author keywords

Acacia dietary fiber; Bifidobacterium lactis; Irritable bowel syndrome; Probiotics; Yogurt

Indexed keywords

PROBIOTIC AGENT; YOGHURT;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ACACIA; ADULT; AGED; ARTICLE; BACTERIUM CULTURE; BIFIDOBACTERIUM ANIMALIS; BLOATING; CLINICAL EVALUATION; CONSTIPATION; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEFECATION HABIT; DIARRHEA; DIETARY FIBER; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FECES ANALYSIS; FEMALE; FLATULENCE; FOOD INTAKE; HUMAN; IRRITABLE COLON; LACTOBACILLUS ACIDOPHILUS; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL; STREPTOCOCCUS THERMOPHILUS; STRUCTURED QUESTIONNAIRE; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

EID: 84867731927     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i33.4563     Document Type: Article

References (36)

1. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999; 45 Suppl 2: II43-II47
2. Mönnikes H. Quality of life in patients with irritable bowel syndrome. J Clin Gastroenterol 2011; 45 Suppl: S98-101
3. Moayyedi P, Ford AC. Symptom-based diagnostic criteria for irritable bowel syndrome: the more things change, the more they stay the same. Gastroenterol Clin North Am 2011; 40: 87-103
4. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 2108-2131
5. Gasbarrini A, Lauritano EC, Garcovich M, Sparano L, Gasbarrini G. New insights into the pathophysiology of IBS: intestinal microflora, gas production and gut motility. Eur Rev Med Pharmacol Sci 2008; 12 Suppl 1: 111-117
6. Barbara G, De Giorgio R, Stanghellini V, Cremon C, Salvioli B, Corinaldesi R. New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther 2004; 20 Suppl 2: 1-9
7. Dahlqvist G, Piessevaux H. Irritable bowel syndrome: the role of the intestinal microbiota, pathogenesis and therapeutic targets. Acta Gastroenterol Belg 2011; 74: 375-380
8. Wouters MM. New insight in the pathogenesis of functional gastrointestinal disorders: association between genetics and colonic transit. Neurogastroenterol Motil 2011; 23: 893-897
9. Chang JY, Talley NJ. Current and emerging therapies in irritable bowel syndrome: from pathophysiology to treatment. Trends Pharmacol Sci 2010; 31: 326-334
10. Meier R. Probiotics in irritable bowel syndrome. Ann Nutr Metab 2010; 57 Suppl: 12-13
11. Quigley EM. Gut microbiota and the role of probiotics in therapy. Curr Opin Pharmacol 2011; 11: 593-603
12. Girardin M, Seidman EG. Indications for the use of probiotics in gastrointestinal diseases. Dig Dis 2011; 29: 574-587
13. Aragon G, Graham DB, Borum M, Doman DB. Probiotic therapy for irritable bowel syndrome. Gastroenterol Hepatol (N Y) 2010; 6: 39-44
14. Sinn DH, Song JH, Kim HJ, Lee JH, Son HJ, Chang DK, Kim YH, Kim JJ, Rhee JC, Rhee PL. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci 2008; 53: 2714-2718
15. Quigley EM. The use of probiotics in functional bowel disease. Gastroenterol Clin North Am 2005; 34: 533-545, x
16. Berrada N, Lemeland JF, Laroche G, Thouvenot P, Piaia M. Bifidobacterium from fermented milks: survival during gastric transit. J Dairy Sci 1991; 74: 409-413
17. Pochart P, Marteau P, Bouhnik Y, Goderel I, Bourlioux P, Rambaud JC. Survival of bifidobacteria ingested via fermented milk during their passage through the human small intestine: an in vivo study using intestinal perfusion. Am J Clin Nutr 1992; 55: 78-80
18. Marteau P, Cuillerier E, Meance S, Gerhardt MF, Myara A, Bouvier M, Bouley C, Tondu F, Bommelaer G, Grimaud JC. Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. Aliment Pharmacol Ther 2002; 16: 587-593
19. Guyonnet D, Chassany O, Ducrotte P, Picard C, Mouret M, Mercier CH, Matuchansky C. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007; 26: 475-486
20. Phillips GO. Acacia gum (Gum Arabic): a nutritional fibre; metabolism and calorific value. Food Addit Contam 1998; 15: 251-264
21. Goetze O, Fruehauf H, Pohl D, Giarrè M, Rochat F, Ornstein K, Menne D, Fried M, Thumshirn M. Effect of a prebiotic mixture on intestinal comfort and general wellbeing in health. Br J Nutr 2008; 100: 1077-1085
22. Camilleri M. Management of the irritable bowel syndrome. Gastroenterology 2001; 120: 652-668
23. Zuckerman MJ. The role of fiber in the treatment of irritable bowel syndrome: therapeutic recommendations. J Clin Gastroenterol 2006; 40: 104-108
24. Choi SC, Kim BJ, Rhee PL, Chang DK, Son HJ, Kim JJ, Rhee JC, Kim SI, Han YS, Sim KH, Park SN. Probiotic Fermented Milk Containing Dietary Fiber Has Additive Effects in IBS with Constipation Compared to Plain Probiotic Fermented Milk. Gut Liver 2011; 5: 22-28
25. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006; 130: 1377-1390
26. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-1491
27. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997; 32: 920-924
28. Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, Thomforde GM, Zinsmeister AR. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17: 895-904
29. Agrawal A, Houghton LA, Morris J, Reilly B, Guyonnet D, Goupil Feuillerat N, Schlumberger A, Jakob S, Whorwell PJ. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2009; 29: 104-114
30. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O'Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-551
31. Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, Kiely B, Shanahan F, Quigley EM. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006; 101: 1581-1590
32. Guyonnet D, Schlumberger A, Mhamdi L, Jakob S, Chassany O. Fermented milk containing Bifidobacterium lactis DN-173 010 improves gastrointestinal well-being and digestive symptoms in women reporting minor digestive symptoms: a randomised, double-blind, parallel, controlled study. Br J Nutr 2009; 102: 1654-1662
33. Cann PA, Read NW, Holdsworth CD. What is the benefit of coarse wheat bran in patients with irritable bowel syndrome? Gut 1984; 25: 168-173
34. Francis CY, Whorwell PJ. Bran and irritable bowel syndrome: time for reappraisal. Lancet 1994; 344: 39-40
35. Bijkerk CJ, Muris JW, Knottnerus JA, Hoes AW, de Wit NJ. Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004; 19: 245-251
36. Spiller RC. Pharmacology of dietary fibre. Pharmacol Ther 1994; 62: 407-427